Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Core Insights - Daré Bioscience, Inc. will host a conference call on March 31, 2025, to review its financial results for the year ended December 31, 2024, and provide a company update [1] - The company focuses on advancing innovative products for women's health, aiming to develop a diverse portfolio of therapies that improve treatment options and outcomes [3] Financial Results and Conference Call - The conference call will take place at 4:30 p.m. Eastern Time, and participants can access it via phone or live webcast [2] - The webcast will be archived and available for replay until April 14, 2025 [2] Product Portfolio - Daré's first FDA-approved product is XACIATO™, a vaginal gel for treating bacterial vaginosis, under a global license agreement with Organon [4] - The company is developing several first-in-category candidates, including Ovaprene, Sildenafil Cream, and DARE-HRT1, targeting various aspects of women's health [4] Recognition and Leadership - Daré Bioscience leadership has received accolades, including being named on Medicine Maker's Power List and recognition for contributions to women's health innovation [5] - The CEO was honored as one of Fierce Pharma's Most Influential People in Biopharma in 2023 [5] - The company was ranked 1 in the Small Company category of the San Diego Business Journal's 2023 Best Places to Work Awards [5] Communication Channels - Daré will announce material information through its Investors section, SEC filings, press releases, and social media [6] - The company encourages stakeholders to review the information posted on its investor relations website and follow its social media accounts for updates [6]